Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.48 |
| ▸ | REN | P00797 | 6/20 | 0.45 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.43 |
| ▸ | ITGB2 | P05107 | 2/20 | 0.42 |
| ▸ | ICAM1 | P05362 | 2/20 | 0.42 |
| ▸ | ITGAL | P20701 | 2/20 | 0.42 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11117873 | 0.81 | HRH3 (0.47) | CYP3A4ALDH1A1CYP1A2SLC7A5 | |
| SCHEMBL17119231 | 0.81 | HRH3 (0.47) | CYP3A4ALDH1A1CYP1A2SLC7A5 | |
| SCHEMBL31056938 | 0.78 | CTSL (0.45) | SLC15A2RENSLC6A5ACE2 | |
| SCHEMBL26312334 | 0.78 | SLC15A2 (0.64) | SLC15A2RENCYP3A4SLC7A5 | |
| SCHEMBL1666697 | 0.77 | ALDH1A1 (0.58) | SLC15A2SLC6A5ITGB2ICAM1ITGAL | |
| SCHEMBL18748750 | 0.77 | CYP3A4 (0.49) | RENSLC6A5ITGB2ICAM1ITGAL | |
| SCHEMBL14883199 | 0.77 | CA1 (0.51) | SLC15A2RENITGB2ICAM1ITGAL | |
| SCHEMBL14883104 | 0.77 | CA1 (0.51) | SLC15A2RENITGB2ICAM1ITGAL | |
| SCHEMBL13863500 | 0.76 | CYP3A4 (0.46) | ITGB2ICAM1ITGALCYP3A4ALDH1A1 | |
| SCHEMBL508741 | 0.76 | HRH3 (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9731029-B2 | Protein retrosplicing enabled by a double ligation reaction | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2017-08-15 | — | — | US | disclosed |
| US-20150152134-A1 | PROTEIN RETROSPLICING ENABLED BY A DOUBLE LIGATION REACTION | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152134-A1 | PROTEIN RETROSPLICING ENABLED BY A DOUBLE LIGATION REACTION | COASY, LYPLA1, LYPLA2 | SLC15A2 2201/4885REN 2039/4885SLC6A5 2212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.